BR9807974A - Composição farmacêutica para liberação prolongada de um derivado de eritromicina no ambiente gastrointestinal, e, processo para utilizar a mesma - Google Patents

Composição farmacêutica para liberação prolongada de um derivado de eritromicina no ambiente gastrointestinal, e, processo para utilizar a mesma

Info

Publication number
BR9807974A
BR9807974A BR9807974-3A BR9807974A BR9807974A BR 9807974 A BR9807974 A BR 9807974A BR 9807974 A BR9807974 A BR 9807974A BR 9807974 A BR9807974 A BR 9807974A
Authority
BR
Brazil
Prior art keywords
erythromycin derivative
composition
pharmaceutical composition
prolonged release
same
Prior art date
Application number
BR9807974-3A
Other languages
English (en)
Inventor
Laman A Al-Razzak
Sheri L Crampton
Linda E Gustavson
Ho-Wah Hui
Nelly Milman
Susan J Semla
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25278344&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9807974(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of BR9807974A publication Critical patent/BR9807974A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)

Abstract

"COMPOSIçãO FARMACêUTICA PARA LIBERAçãO PROLONGADA DE UM DERIVADO DE ERITROMICINA NO AMBIENTE GASTROINTESTINAL, E, PROCESSO PARA UTILIZAR A MESMA". é descrita uma composição farmacêutica para liberação prolongada de um derivado de eritromicina no ambiente gastrointestinal. A composição compreende um derivado de eritromicina e um polímero farmaceuticamente aceitável, de modo que, quando ingerida oralmente, a composição induz C~ max~ estatística e significativamente mais baixa no plasma do que uma composição de liberação imediata do derivado de eritromicina, enquanto mantendo a biodisponibilidade e concentração mínima substancialmente equivalentes à da composição de liberação imediata do derivado de eritromicina quando de múltipla dosagem. As composições da invenção têm um perfil de paladar melhorado e reduzidos efeitos colaterais gastrointestinais, em comparação com aqueles da composição de liberação imediata.
BR9807974-3A 1997-04-11 1998-03-06 Composição farmacêutica para liberação prolongada de um derivado de eritromicina no ambiente gastrointestinal, e, processo para utilizar a mesma BR9807974A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/838,900 US6010718A (en) 1997-04-11 1997-04-11 Extended release formulations of erythromycin derivatives
PCT/US1998/004373 WO1998046239A1 (en) 1997-04-11 1998-03-06 Extended release formulations of erythromycin derivatives

Publications (1)

Publication Number Publication Date
BR9807974A true BR9807974A (pt) 2000-03-08

Family

ID=25278344

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9807974-3A BR9807974A (pt) 1997-04-11 1998-03-06 Composição farmacêutica para liberação prolongada de um derivado de eritromicina no ambiente gastrointestinal, e, processo para utilizar a mesma

Country Status (29)

Country Link
US (1) US6010718A (pt)
EP (2) EP0973527B1 (pt)
JP (2) JP4394754B2 (pt)
KR (1) KR100484559B1 (pt)
CN (1) CN100408044C (pt)
AR (1) AR012358A1 (pt)
AT (1) ATE253371T1 (pt)
AU (1) AU737324B2 (pt)
BG (1) BG65188B1 (pt)
BR (1) BR9807974A (pt)
CA (1) CA2285266C (pt)
CO (1) CO4940403A1 (pt)
CZ (1) CZ294333B6 (pt)
DE (1) DE69819481T2 (pt)
DK (1) DK0973527T3 (pt)
ES (1) ES2205454T3 (pt)
HK (1) HK1027023A1 (pt)
HU (1) HUP0001382A3 (pt)
IL (3) IL131616A0 (pt)
NO (1) NO994946D0 (pt)
NZ (3) NZ596215A (pt)
PL (2) PL336142A1 (pt)
PT (1) PT973527E (pt)
SA (1) SA98190065B1 (pt)
SK (2) SK288127B6 (pt)
TR (2) TR199902149T2 (pt)
TW (1) TW576743B (pt)
WO (1) WO1998046239A1 (pt)
ZA (1) ZA982916B (pt)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU773863B2 (en) * 1997-04-11 2004-06-10 Bgp Products Operations Gmbh Extended release formulations of erythromycin derivatives
US6551616B1 (en) * 1997-04-11 2003-04-22 Abbott Laboratories Extended release formulations of erythromycin derivatives
US6099859A (en) * 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
TR200000054A2 (tr) * 2000-01-05 2001-08-21 Sanovel İlaç San. Ve Ti̇c. Anoni̇m Şi̇rketi̇ Klaritromisin içeren sürekli salım sağlayan tablet formülasyonları.
US6565882B2 (en) * 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
US6544555B2 (en) * 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
IL151496A0 (en) * 2000-02-29 2003-04-10 Teva Pharma Processes for preparing clarithromycin and clarithromycin intermediate, essentially oxime-free clarithromycin, and pharmaceutical composition comprising the same
DE60138876D1 (de) * 2000-03-28 2009-07-16 Sandoz Ag Geschmackmaskierte granulierte teilchen
IN192748B (pt) * 2000-08-29 2004-05-15 Ranbaxy Lab Ltd
US6541014B2 (en) * 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
CA2425688A1 (en) * 2000-10-13 2002-05-16 Donald J. Treacy Jr. Extended release erythromycin derivatives
US20020068078A1 (en) * 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US6866866B1 (en) * 2000-11-03 2005-03-15 Andrx Labs, Llc Controlled release metformin compositions
US6790459B1 (en) 2000-11-03 2004-09-14 Andrx Labs, Llc Methods for treating diabetes via administration of controlled release metformin
US20060034922A1 (en) * 2000-11-03 2006-02-16 Andrx Labs, Llc Controlled release metformin compositions
US20020197314A1 (en) * 2001-02-23 2002-12-26 Rudnic Edward M. Anti-fungal composition
US6673369B2 (en) 2001-08-29 2004-01-06 Ranbaxy Laboratories Limited Controlled release formulation
EP1423097A1 (en) * 2001-08-29 2004-06-02 Ranbaxy Laboratories, Ltd. Controlled release formulation of clarithromycin or tinidazol
US20050249786A1 (en) * 2001-09-28 2005-11-10 Solubest Ltd. Hydrophilic dispersions of nanoparticles of inclusion complexes of amorphous compounds
US20050191359A1 (en) * 2001-09-28 2005-09-01 Solubest Ltd. Water soluble nanoparticles and method for their production
US20050233003A1 (en) * 2001-09-28 2005-10-20 Solubest Ltd. Hydrophilic dispersions of nanoparticles of inclusion complexes of salicylic acid
US20050227911A1 (en) * 2001-09-28 2005-10-13 Solubest Ltd. Hydrophilic dispersions of nanoparticles of inclusion complexes of macromolecules
US6878693B2 (en) * 2001-09-28 2005-04-12 Solubest Ltd. Hydrophilic complexes of lipophilic materials and an apparatus and method for their production
US7037523B2 (en) * 2001-11-02 2006-05-02 Wockhardt Limited Controlled release compositions for macrolide antimicrobial agents
US7700851B2 (en) * 2001-11-13 2010-04-20 U.S. Smokeless Tobacco Company Tobacco nicotine demethylase genomic clone and uses thereof
AU2003225837B2 (en) * 2002-03-15 2008-11-06 Forest Laboratories Holdings Limited NE and 5-HT reuptake inhibitors for treating visceral pain syndromes
AU2003241537A1 (en) * 2002-05-23 2003-12-12 Andrx Corporation Biguanide formulations
AU2003245504A1 (en) * 2002-06-14 2003-12-31 Andrx Corporation Pharmaceutical compositions for drugs having ph-dependentsolubility
US20060003004A1 (en) * 2002-10-25 2006-01-05 Collegium Pharmaceutical, Inc. Pulsatile release compositions of milnacipran
US20040132826A1 (en) * 2002-10-25 2004-07-08 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
US9561182B2 (en) * 2003-08-22 2017-02-07 Cure Pharmaceutical Corporation Edible films for administration of medicaments to animals, methods for their manufacture and methods for their use for the treatment of animals
US20040131662A1 (en) 2003-11-12 2004-07-08 Davidson Robert S. Method and apparatus for minimizing heat, moisture, and shear damage to medicants and other compositions during incorporation of same with edible films
US8999372B2 (en) * 2002-11-14 2015-04-07 Cure Pharmaceutical Corporation Methods for modulating dissolution, bioavailability, bioequivalence and drug delivery profile of thin film drug delivery systems, controlled-release thin film dosage formats, and methods for their manufacture and use
US20040191302A1 (en) 2003-03-28 2004-09-30 Davidson Robert S. Method and apparatus for minimizing heat, moisture, and shear damage to medicants and other compositions during incorporation of same with edible films
AU2004207578B2 (en) * 2003-01-28 2007-06-28 Collegium Pharmaceutical, Inc. Multiparticulate compositions of milnacipran for oral administration
US20040185097A1 (en) * 2003-01-31 2004-09-23 Glenmark Pharmaceuticals Ltd. Controlled release modifying complex and pharmaceutical compositions thereof
WO2004100880A2 (en) * 2003-05-06 2004-11-25 Nirmal Mulye Controlled release formulation of erythromycin derivatives
US7063862B2 (en) * 2003-06-03 2006-06-20 Biokey, Inc. Pharmaceutical composition and method for treating
EP1638529B1 (en) * 2003-06-16 2016-08-10 ANDRX Pharmaceuticals, LLC. Oral extended-release composition
US20050053658A1 (en) * 2003-09-09 2005-03-10 Venkatesh Gopi M. Extended release systems for macrolide antibiotics
WO2005009365A2 (en) * 2003-07-21 2005-02-03 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
US8425936B2 (en) * 2003-07-21 2013-04-23 Shionogi Inc. Antibiotic product, use and formulation thereof
EP1648407A4 (en) * 2003-07-21 2011-08-31 Middlebrook Pharmaceuticals Inc ANTIBIOTIC PRODUCT, CORRESPONDING USE AND FORMULATION
CA2535177A1 (en) * 2003-08-11 2005-02-24 Advancis Pharmaceutical Corporation Robust pellet
JP2007502294A (ja) 2003-08-12 2007-02-08 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
WO2005023184A2 (en) * 2003-08-29 2005-03-17 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
WO2005023221A1 (en) * 2003-09-05 2005-03-17 Ranbaxy Laboratories Limited Clarithromycin formulations having improved biovailability
JP2007513869A (ja) * 2003-09-15 2007-05-31 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
US8168228B2 (en) * 2003-10-17 2012-05-01 Sandoz Ag Antibiotic clarithromycin micropellet compositions
US20050084540A1 (en) * 2003-10-17 2005-04-21 Indranil Nandi Taste masking antibiotic composition
AU2004286855B2 (en) * 2003-10-29 2011-04-21 Wyeth Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof
US20050101547A1 (en) * 2003-11-06 2005-05-12 Sadatrezaei Mohsen Stabilized azithromycin composition
JP2007513147A (ja) * 2003-12-04 2007-05-24 ファイザー・プロダクツ・インク 押し出し機を使用して、好ましくはポロキサマーとグリセリドを含有する多粒子結晶性医薬組成物を製造するための噴霧凝結方法
SI1691787T1 (sl) * 2003-12-04 2008-10-31 Pfizer Prod Inc Postopek za pripravo farmacevtskih produktov iz več delcev
WO2005053652A1 (en) 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride
EP1691786A1 (en) * 2003-12-04 2006-08-23 Pfizer Products Inc. Multiparticulate compositions with improved stability
US6984403B2 (en) * 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects
WO2005053639A2 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Controlled release multiparticulates formed with dissolution enhancers
BRPI0416535A (pt) * 2003-12-04 2007-01-09 Pfizer Prod Inc processo de congelamento por vaporização empregando um extrusor para preparar composições de azitromicina de multiparticulado contendo preferivelmente um poloxámero e um glicerìdeo
BRPI0417338A (pt) * 2003-12-04 2007-04-17 Pfizer Prod Inc formas de dosagem de azitromicina multiparticulada por processos a base de lìquido
US7943585B2 (en) 2003-12-22 2011-05-17 Sandoz, Inc. Extended release antibiotic composition
WO2005062898A2 (en) * 2003-12-24 2005-07-14 Advancis Pharmaceutical Corporation Enhanced absorption of modified release dosage forms
AU2005235237A1 (en) * 2004-03-24 2005-11-03 Lupin Limited Clarithromycin extended release formulation
US20050260263A1 (en) * 2004-05-18 2005-11-24 Panion & Bf Biotech Inc. Sustained release formulation for sparingly soluble main drugs
KR101122096B1 (ko) * 2004-05-20 2012-03-15 주식회사종근당 쓴맛을 차폐하면서 우수한 용출률을 보이는클라리스로마이신의 약제학적 조성물 및 그의 제조 방법
KR100621342B1 (ko) * 2004-06-22 2006-09-18 (주)다산메디켐 클래리스로마이신-함유 약제학적 조성물 및 그의 제조방법
US8715727B2 (en) * 2004-07-02 2014-05-06 Shionogi Inc. Tablet for pulsed delivery
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US8778924B2 (en) * 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
JPWO2007126039A1 (ja) * 2006-04-28 2009-09-10 塩野義製薬株式会社 マクロライド系抗生物質の被覆製剤
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
EP2023721A2 (en) * 2006-06-05 2009-02-18 Auspex Pharmaceuticals Inc. Preparation and utility of substituted erythromycin analogs
EP2283824B1 (en) 2009-07-30 2017-04-19 Special Products Line S.p.A. Compositions and formulations based on swellable matrices for sustained release of poorly soluble drugs such as clarithromycin
EP2671571A1 (en) 2012-06-05 2013-12-11 Sanovel Ilac Sanayi ve Ticaret A.S. Controlled-release formulations of clarithromycin

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3870790A (en) * 1970-01-22 1975-03-11 Forest Laboratories Solid pharmaceutical formulations containing hydroxypropyl methyl cellulose
US4226849A (en) * 1979-06-14 1980-10-07 Forest Laboratories Inc. Sustained release therapeutic compositions
US4369172A (en) * 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
DE3583799D1 (de) * 1985-01-11 1991-09-19 Abbott Lab Ltd Feste zubereitung mit langsamer freisetzung.
FR2585948B1 (fr) * 1985-08-06 1988-12-16 Pf Medicament Procede de fabrication de comprimes d'indometacine
US4808411A (en) * 1987-06-05 1989-02-28 Abbott Laboratories Antibiotic-polymer compositions
US4925675A (en) 1988-08-19 1990-05-15 Himedics, Inc. Erythromycin microencapsulated granules
JP3265680B2 (ja) * 1992-03-12 2002-03-11 大正製薬株式会社 経口製剤用組成物
US5393765A (en) * 1993-12-13 1995-02-28 Hoffmann-La Roche Inc. Pharmaceutical compositions with constant erosion volume for zero order controlled release
ES2163504T5 (es) * 1994-05-06 2008-05-16 Pfizer Inc. Formas de dosificacion de liberacion controlada de azitromicina.
JPH0995440A (ja) * 1995-09-29 1997-04-08 Roussel Morishita Kk 徐放性製剤およびその製造方法
US5919489A (en) * 1995-11-01 1999-07-06 Abbott Laboratories Process for aqueous granulation of clarithromycin
US5705190A (en) * 1995-12-19 1998-01-06 Abbott Laboratories Controlled release formulation for poorly soluble basic drugs
US5972389A (en) * 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter

Also Published As

Publication number Publication date
EP1340495A1 (en) 2003-09-03
HUP0001382A3 (en) 2001-08-28
IL131616A0 (en) 2001-01-28
TW576743B (en) 2004-02-21
KR20010006251A (ko) 2001-01-26
NO994946L (no) 1999-10-11
SK288109B6 (sk) 2013-08-02
NZ337120A (en) 2001-04-27
AU6346398A (en) 1998-11-11
BG65188B1 (bg) 2007-06-29
CZ294333B6 (cs) 2004-12-15
JP2009137988A (ja) 2009-06-25
AU737324B2 (en) 2001-08-16
CZ347199A3 (cs) 2000-01-12
BG103862A (en) 2000-07-31
SA98190065B1 (ar) 2006-06-17
IL131616A (en) 2013-03-24
DE69819481D1 (de) 2003-12-11
DK0973527T3 (da) 2003-11-24
ZA982916B (en) 1998-10-09
DE69819481T2 (de) 2004-08-26
IL223035A0 (en) 2012-12-31
EP1340495B1 (en) 2016-08-10
PL336142A1 (en) 2000-06-05
TR199902149T2 (xx) 1999-12-21
CN1494911A (zh) 2004-05-12
JP4394754B2 (ja) 2010-01-06
KR100484559B1 (ko) 2005-04-22
ES2205454T3 (es) 2004-05-01
EP0973527A1 (en) 2000-01-26
CA2285266A1 (en) 1998-10-22
AR012358A1 (es) 2000-10-18
CO4940403A1 (es) 2000-07-24
NZ537410A (en) 2007-06-29
WO1998046239A1 (en) 1998-10-22
ATE253371T1 (de) 2003-11-15
JP2001524955A (ja) 2001-12-04
CN100408044C (zh) 2008-08-06
PT973527E (pt) 2004-01-30
CA2285266C (en) 2001-07-24
US6010718A (en) 2000-01-04
HUP0001382A2 (hu) 2000-09-28
NO994946D0 (no) 1999-10-11
HK1027023A1 (en) 2001-01-05
SK288127B6 (sk) 2013-10-02
SK138099A3 (en) 2000-04-10
TR200707263T2 (tr) 2008-01-21
EP0973527B1 (en) 2003-11-05
PL402949A1 (pl) 2013-04-15
JP5188994B2 (ja) 2013-04-24
NZ596215A (en) 2013-09-27

Similar Documents

Publication Publication Date Title
BR9807974A (pt) Composição farmacêutica para liberação prolongada de um derivado de eritromicina no ambiente gastrointestinal, e, processo para utilizar a mesma
BR0010485A (pt) Formulações de derivados de eritromicina de liberação prolongada
BR0008059A (pt) Composições de valdecoxib
HUP0003323A2 (hu) Vorikonazolt tartalmazó gyógyászati készítmények
EA200900264A1 (ru) Композиции флибансерина и способ их приготовления
BR9908438A (pt) Tabletes de desintegração rápida
DE69604653D1 (de) Taxol derivate, deren herstellung und diese enthaltende pharmazeutischen zusammenstellungen
BR9713147A (pt) Benzamidoaldeìdo, uso do mesmo, benzamida, e, preparação medicamentosa para administração oral, parenteral ou intraperitoneal.
EP1685839B8 (en) Pharmaceutical oral dosage form comprising a combination of an opioid agonist and opioid antagonist
BR9908030A (pt) Composição farmacêutica compreendendo uma ou mais unidades de dose oralmente ministráveis, e, processos para prepará-la, para uso da mesma, e para tratar uma condição ou distúrbio médico em um indivìduo em que tratamento com um inibidor da ciclooxigenase-2 é indicado
HUP0000138A2 (hu) Szabályozott hatóanyag-leadású opioid analgetikumokat tartalmazó gyógyászati készítmények
NO330947B1 (no) Anvendelse av farmasoytiske sammensetninger som inneholder okskarbazepin, i fastende tilstand
BR0013355A (pt) Tratamento com droga para a sìndrome da perna inquieta
BG104620A (en) Oral pharmaceutical extended release dosage form
CO5170471A1 (es) Tabletas de liberacion modificada que incluyen amoxilina y clavulanato de potasio
TR199801861T2 (xx) Farmas�tik olarak yararl� bile�imler.
BR0312728A (pt) Formulação em tablete dispersìvel e processo para sua preparação
BR0211198A (pt) Composições farmacêuticas e seu uso
BR9809571A (pt) Composição medicinal e processo para produzì-la
NO20045385L (no) Farmasoytisk preparat inneholdende okskarbazepin med kontrollert frigivelse av aktivt stoff
PT1425005E (pt) Composicao farmaceutica que compreende lumiracoxib
CO5540294A2 (es) Una combinacion de un derivado de rapamicina y un agente alquilante seleccionado de ciclofosfamida y carmustina y composiciones que las contienen
BR9810337A (pt) Utilização de um antagonista especìfico dos receptores 5ht2 para a preparação de medicamentos úteis no tratamento da sìndrome de apnéia do sono
BR0111051A (pt) Produto farmacêutico e dose farmacêutica diária para administração a um paciente, regime de dose prover um efeito anti-androgênico e um efeito anti-estrogênico em um paciente, uso de um composto e de tamoxifeno ou de um sal ou solvato farmaceuticamente aceitável destes, e, método para prover um efeito anti-androgênico em um paciente
BRPI9916820B8 (pt) composição compreendendo 9[2[[bis[(pivaloilóxi)metil]fosfono]metóxi]etil]adenina, comprimido ou cápsula e método

Legal Events

Date Code Title Description
FA Application withdrawn
B15K Others concerning applications: alteration of classification

Ipc: A61K 31/7048 (2006.01), A61K 9/20 (2006.0